Compare Panacea Biotech with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs ALEMBIC PHARMA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH ALEMBIC PHARMA PANACEA BIOTECH/
ALEMBIC PHARMA
 
P/E (TTM) x 11.5 16.3 70.6% View Chart
P/BV x 2.8 3.7 73.8% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 PANACEA BIOTECH   ALEMBIC PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
ALEMBIC PHARMA
Mar-19
PANACEA BIOTECH/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs364664 54.8%   
Low Rs129412 31.3%   
Sales per share (Unadj.) Rs96.8208.7 46.4%  
Earnings per share (Unadj.) Rs-12.431.0 -40.0%  
Cash flow per share (Unadj.) Rs-2.937.1 -7.7%  
Dividends per share (Unadj.) Rs05.50 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs50.4144.2 34.9%  
Shares outstanding (eoy) m61.25188.52 32.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.52.6 98.8%   
Avg P/E ratio x-19.917.4 -114.4%  
P/CF ratio (eoy) x-86.414.5 -596.0%  
Price / Book Value ratio x4.93.7 131.1%  
Dividend payout %017.7 0.0%   
Avg Mkt Cap Rs m15,101101,461 14.9%   
No. of employees `0002.5NA-   
Total wages/salary Rs m1,5167,467 20.3%   
Avg. sales/employee Rs Th2,401.9NM-  
Avg. wages/employee Rs Th614.2NM-  
Avg. net profit/employee Rs Th-307.9NM-  
INCOME DATA
Net Sales Rs m5,92839,347 15.1%  
Other income Rs m8294 87.7%   
Total revenues Rs m6,01039,441 15.2%   
Gross profit Rs m8458,736 9.7%  
Depreciation Rs m5851,152 50.8%   
Interest Rs m1,006184 546.3%   
Profit before tax Rs m-6647,493 -8.9%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m2-93 -2.3%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m991,568 6.3%   
Profit after tax Rs m-7605,844 -13.0%  
Gross profit margin %14.322.2 64.2%  
Effective tax rate %-14.920.9 -71.0%   
Net profit margin %-12.814.9 -86.3%  
BALANCE SHEET DATA
Current assets Rs m5,60319,577 28.6%   
Current liabilities Rs m6,91014,896 46.4%   
Net working cap to sales %-22.011.9 -185.3%  
Current ratio x0.81.3 61.7%  
Inventory Days Days20690 229.3%  
Debtors Days Days8445 184.7%  
Net fixed assets Rs m9,94127,097 36.7%   
Share capital Rs m61377 16.3%   
"Free" reserves Rs m3,02626,811 11.3%   
Net worth Rs m3,08727,188 11.4%   
Long term debt Rs m5,7074,993 114.3%   
Total assets Rs m16,07647,778 33.6%  
Interest coverage x0.341.7 0.8%   
Debt to equity ratio x1.80.2 1,006.7%  
Sales to assets ratio x0.40.8 44.8%   
Return on assets %1.512.6 12.1%  
Return on equity %-24.621.5 -114.5%  
Return on capital %3.923.6 16.6%  
Exports to sales %24.00-   
Imports to sales %17.50-   
Exports (fob) Rs m1,424NA-   
Imports (cif) Rs m1,040NA-   
Fx inflow Rs m1,60019,453 8.2%   
Fx outflow Rs m1,1316,065 18.7%   
Net fx Rs m46913,388 3.5%   
CASH FLOW
From Operations Rs m1,1808,120 14.5%  
From Investments Rs m553-7,556 -7.3%  
From Financial Activity Rs m-1,644590 -278.4%  
Net Cashflow Rs m901,153 7.8%  

Share Holding

Indian Promoters % 74.5 74.1 100.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 2.9 20.7%  
FIIs % 1.3 9.1 14.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 13.9 169.8%  
Shareholders   10,259 49,328 20.8%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   TORRENT PHARMA  ALKEM LABORATORIES  ELDER PHARMA  SANOFI INDIA  DR. DATSONS LABS  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Oct 18, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS